GHRP-2 / Pralmorelin
Growth Hormone Secretagogue (GHS)
Overview
GHRP-2 is one of the most potent synthetic growth hormone secretagogues ever studied — a six-amino-acid peptide that tells your pituitary gland to release a pulse of growth hormone by mimicking ghrelin, the body's own "hunger hormone." That's a meaningful distinction from GHRH-based peptides: GHRP-2 works through an entirely different receptor, which is why researchers have long been interested in combining the two approaches.
In Japan, it's been approved under the name Pralmorelin as a diagnostic agent for growth hormone deficiency testing.[1] In the United States, GHRP-2 carries no FDA approval and is classified for research purposes only. It's not available through compounding pharmacies or by prescription for therapeutic use in the US.
Despite that status, GHRP-2 has shown up in nutritional supplements and black-market injection products — a pattern that reflects both genuine interest in its GH-releasing effects and the risks that come with unregulated sourcing.[2][3]
Mechanism of Action
GHS-R1a (ghrelin receptor) agonism → Gq/PLC/calcium signaling → GH pulse
The key to understanding GHRP-2 is understanding what it's binding to. Most people assume growth hormone secretagogues all work the same way — they don't. GHRP-2 targets the ghrelin receptor, formally called GHS-R1a, which is distinct from the GHRH receptor that peptides like CJC-1295 activate.[4] That distinction matters because the two pathways are additive: hit both at once and you get a larger GH pulse than either alone can produce.
When GHRP-2 binds GHS-R1a, it activates a Gq protein, which triggers phospholipase C (PLC) and ultimately causes a spike in intracellular calcium inside pituitary somatotroph cells.[4] That calcium surge is what drives the release of stored growth hormone. The whole process happens quickly — GH levels typically peak within 15–30 minutes of injection, though the time to peak GH levels following GHRP-2 administration has not been established in published human clinical data — and the pulse is transient, mimicking the body's natural episodic GH secretion pattern rather than producing a sustained flat elevation.
This pulsatile release is actually considered an advantage over exogenous recombinant human growth hormone (rhGH). Continuous supraphysiologic GH exposure blunts the pituitary's own regulatory feedback. Secretagogues like GHRP-2 work within the body's existing feedback architecture — if GH levels are already high, the response is blunted naturally.[5] That self-limiting quality is part of why researchers view GH secretagogues as potentially safer than direct GH administration, though long-term human data to confirm that hypothesis remains limited.
One thing you can't separate from GHRP-2's mechanism: it's activating the same receptor that ghrelin activates, and ghrelin is a potent appetite stimulant. Increased hunger is not an incidental side effect — it's a direct pharmacological consequence of what GHRP-2 does.
What the Evidence Shows
Most of the published human data on GHRP-2 comes from two contexts: short-term GH stimulation studies in healthy volunteers or GH-deficient patients, and the Japanese diagnostic approval for Pralmorelin.
The Pralmorelin diagnostic application is the most clinically validated use. A single 100 mcg intravenous dose reliably produces a measurable GH pulse, making it useful for distinguishing true GH deficiency from normal pituitary function.[1] This is the only approved indication anywhere in the world.
In research settings, GHRP-2 has consistently demonstrated dose-dependent GH release in healthy adults, with the GH response blunted by hyperglycemia and augmented by co-administration of GHRH.[5] Studies examining the cortisol and prolactin co-secretion — which occurs with most GHRPs — have found that GHRP-2 produces these elevations, though the clinical significance in short-term use remains debated.[5]
The receptor biology has been well characterized. A key 1998 study confirmed that GHRP-2 does not act through the GHRH receptor, settling an earlier question about its mechanism and establishing that its effects are GHS-R1a-mediated — a finding that underpins the rationale for combination protocols.[4]
Side Effects
If you notice persistent edema, significant changes in fasting glucose, or breast tissue changes (which can occur with sustained prolactin elevation), those are specific reasons to stop use and speak with a physician — not after a few more weeks, immediately.